Page 661 - medicina-integrativa_compress
P. 661

674     PARTE II,  SECCIÓN 11 TRASTORNOS MUSCULOESQUELÉTICOS


                   Una prueba con relajantes musculares.              Aplicación de agujas secas.
                                                      B B  2 2                                            B B  1
                   Posiblemente, una prueba con                       Inyección de solución salina.
                     antiinflamatorios ante exacerbaciones  B B  2 2                                      B B  1
                     agudas.                                          Inyección de anestésicos.
                                                                                                          B B  2 2
                   Fármaco neuromodulador (gabapentina).              Anestésico + corticoides.
                                                      B B  2 2                                            B B  2 2
                                                                      Inyección de toxina botulínica.
                ■ Tratamiento con inyecciones:                                                            B B  2 2
                                                                      • Todos los tratamientos con inyecciones
                   • Cuando los síntomas del paciente
                                                                        deben utilizarse con prudencia y
                     persisten o empeoran a pesar de las                únicamente como parte de una estrategia
                     medidas precedentes, contemplar una                multimodal.
                     intervención basada en el uso de agujas
                     (después de la acupuntura) siguiendo un
                     abordaje escalonado. [Nota: todas las       Todos los tratamientos deben estar bien integrados, con el
                     intervenciones con agujas con posibles      objetivo de mejorar la conciencia del paciente acerca de los
                     efectos beneficiosos se basan en la         desencadenantes biomecánicos y por estrés. Los
                     experiencia del facultativo con el          tratamientos deben pasar gradualmente de pasivos
                     aislamiento de PG. Las lesiones             (dirigidos y supervisados por el médico) a activos
                     normalmente son resultado de la sustancia   (supervisados por el paciente) con una conciencia cada vez
                     utilizada o del uso inapropiado de la       mayor de la capacidad del paciente de abordar y disminuir
                                                                 el ciclo de dolor miofascial.
                     técnica aséptica.]




           BIBLIOGRAFÍA                                        15.  Ferreira DM, Zangaro RA, Villaverde AB, et al: Analgesic effect of
                                                                   He-Ne (632.8 nm) low-level laser therapy on acute inflammatory
            1.  Audette JF, Wang F, Smith H: Bilateral activation of motor unit  pain. Photomed Laser Surg 23:177-181, 2005.
               potentials with unilateral needle stimulation of active myofascial  16.  Passarella S: He-Ne laser irradiation of isolated mitochondria.
               trigger points. Am J Phys Med Rehabil 83:368-374, 2004.  J Photochem Photobiol B 3:642-643, 1989.
            2.  Simmons D, Travell J, Simmons S: Trigger Point Manual, vol 1,   17.  Ceylan Y, Hizmetli S, Silig Y: The effects of infrared laser and
               ed 2. Baltimore, Williams & Wilkins, 1999.          medical treatments on pain and serotonin degradation products
            3.  Tuzun EH, Albayrak G, Eker L, et al: A comparison study of quality  in patients with myofascial pain syndrome: A controlled trial.
               of life in women with fibromyalgia and myofascial pain syndrome.  Rheumatol Int 24:260-263, 2004.
               Disabil Rehabil 26:198-202, 2004.               18.  Ilbuldu E, Cakmak A, Disci R, Aydin R: Comparison of laser, dry
            4.  Pearce JM: Myofascial pain, fibromyalgia or fibrositis? Eur Neurol  needling, and placebo laser treatments in myofascial pain syndrome.
               52:67-72, 2004.                                     Photomed Laser Surg 22:306-311, 2004.
            5.  Nicolakis P, Erdogmus B, Kopf A, et al: Effectiveness of exercise  19.  Airaksinen O, Pontinen PJ: Effects of the electrical stimulation of
               therapy in patients with myofascial pain dysfunction syndrome.   myofascial trigger points with tension headache. Acupunct
               J Oral Rehabil 29:362-368, 2002.                    Electrother Res 17:285-290, 1992.
            6.  Vazquez-Delgado E, Schmidt JE, Carlson CR, et al: Psychological and  20.  Dalpiaz AS, Lordon SP, Lipman AG: Topical lidocaine patch therapy
               sleep quality differences between chronic daily headache and  for myofascial pain. J Pain Palliat Care Pharmacother 18:15-34, 2004.
               temporomandibular disorders patients. Cephalalgia 24:446-454, 2004.  21.  Cannavino CR, Abrams J, Palinkas LA, et al: Efficacy of transdermal
            7.  Lentz MJ, Landis CA, Rothermel J, Shaver JL: Effects of selective  ketoprofen for delayed onset muscle soreness. Clin J Sport Med
               slow wave sleep disruption on musculoskeletal pain and fatigue   13:200-208, 2003.
               in middle aged women. J Rheumatol 26:1586-1592, 1999.  22.  Di Rienzo Businco L, Di Rienzo Businco A, D’Emilia M, et al:
            8.  Fishbain DA, Turner D, Rosomoff HL, Rosomoff RS: Millon  Topical versus systemic diclofenac in the treatment of temporo-
               behavioral health inventory scores of patients with chronic pain  mandibular joint dysfunction symptoms. Acta Otorhinolaryngol Ital
               associated with myofascial pain syndrome. Pain Med 2:328-335,  24:279-283, 2004.
               2001.                                           23.  Mathias BJ, Dillingham TR, Zeigler DN, et al: Topical capsaicin for
            9.  Carlson CR, Bertrand PM, Ehrlich AD, et al: Physical self-regulation  chronic neck pain: A pilot study. Am J Phys Med Rehabil 74:39-44,
               training for the management of temporomandibular disorders.   1995.
               J Orofac Pain 15:47-55, 2001.                   24.  Galeotti N, Di Cesare Mannelli L, Mazzanti G, et al: Menthol: A
           10.  Ryan M, Gevirtz R: Biofeedback-based psychophysiological  natural analgesic compound. Neurosci Lett 322:145-148, 2002.
               treatment in a primary care setting: An initial feasibility study.   25.  Chen JT, Chung KC, Hou CR, et al: Inhibitory effect of dry needling
               Appl Psychophysiol Biofeedback 29:79-93, 2004.      on the spontaneous electrical activity recorded from myofascial
           11.  Baldry P: Management of myofascial trigger point pain. Acupunct  trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil
               Med 20:2-10, 2002.                                  80:729-735, 2001.
           12.  Komiyama O, Kawara M, Arai M, et al: Posture correction as part   26.  Iwama H, Akama Y: The superiority of water-diluted 0.25% to neat
               of behavioural therapy in treatment of myofascial pain with limited  1% lidocaine for trigger-point injections in myofascial pain
               opening. J Oral Rehabil 26:428-435, 1999.           syndrome: A prospective, randomized, double-blinded trial.
           13.  Hou CR, Tsai LC, Cheng KF, et al: Immediate effects of various  Anesth Analg 91:408-409, 2000.
               physical therapeutic modalities on cervical myofascial pain and  27.  Cummings TM, White AR: Needling therapies in the management
               trigger-point sensitivity. Arch Phys Med Rehabil 83:1406-1414, 2002.  of myofascial trigger point pain: A systematic review. Arch Phys
           14.  Hanten WP, Olson SL, Butts NL, Nowicki AL: Effectiveness of a  Med Rehabil 82:986-992, 2001.
               home program of ischemic pressure followed by sustained stretch  28.  Gobel H, Heinze A, Reichel G, et al: Efficacy and safety of a single
               for treatment of myofascial trigger points. Phys Ther 80:997-1003,  botulinum type A toxin complex treatment (Dysport) for the relief
               2000.                                               of upper back myofascial pain syndrome: Results from a randomized
   656   657   658   659   660   661   662   663   664   665   666